| Company/Division name | WuXi Biologics |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Year reshoring announced: | 2021 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 235 |
| Country(ies) from which reshored: | China |
| City reshored to: | Worcester |
| State(s) reshored to: | MA |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | biopharmaceuticals |
| What non-domestic negative factors made offshoring less attractive? | Supply chain interruption risk/Natural disaster risk/Political instability |
| What domestic positive factors made reshoring more attractive? | Customer responsiveness improvement, Proximity to customers/market, covid-19 |
